Clinical trials: Paclitaxel-induced Peripheral Neuropathy
Peripheral Neuropathy Due to Chemotherapy
N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients
The purpose of the study is to evaluate the effect of N-acetyl cysteine in combination with paclitaxel on the clinical outcomes of patients with peripheral neuropathy, paclitaxel-induced peripheral neuropathy affect quality of…
- Trial name
- NCT03492047
- Testing
- low dose N-acetylcysteine, high dose N-acetylcysteine, Paclitaxel
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Ain Shams University
Chemotherapy-induced Peripheral Neuropathy
The Role of TRP Channels in CIPN
Part I: Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in healthy, male volunteers.
- Trial name
- NCT04415892
- Testing
- Cinnamaldehyde and capsaicin
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer, Neuropathy
Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy
Feasibility study to examine the preventative ability of massage therapy on paclitaxel induced peripheral neuropathy in breast cancer
- Conditions
- Breast Cancer, Neuropathy, Neuropathy;Peripheral
- Trial name
- PIPN (NCT03557554)
- Testing
- Massage
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Bryan Schneider
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Concomitant Limb Cryocompression and Scalp Cooling to Reduce Paclitaxel-induced Neuropathy and Alopecia
Paclitaxel is a chemotherapy drug that is used to treat breast cancer, one of the most common cancers. It causes two side effects very often - hair-loss and numbness.
- Trial name
- NCT03248193
- Testing
- Concomitant limb cryocompression and scalp cooling
- Where
- Singapore
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Breast Cancer, Neuropathy;Peripheral
Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy
Taxol is a very effective drug in breast cancer, but it can cause peripheral neuropathy (PN). This toxicity is often dose-limiting.
- Trial name
- NCT06422949
- Testing
- Hilotherm® Cooling treatment
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Chemotherapy Induced Peripheral Neuropathy
Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
The purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel docetaxel chemotherapy to…
- Conditions
- Breast Cancer, Chemotherapy Induced Peripheral Neuropathy, Paclitaxel Induced Neuropathy
- Trial name
- NCT03872141
- Testing
- Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chinese Medicinal Component Relieves CIPN and Mitochondria Function
A randomized controlled trial was designed and conducted to confirm whether oral administration of the herb Moutan Cortex, which contains paeonol, can alleviate peripheral neuropathy in paclitaxel-treated cancer patients.
- Trial name
- NCT07693374
- Testing
- Moutan cortex
- Where
- Taiwan
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
Peripheral Neuropathy, Breast Cancer
Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel.
- Trial name
- NCT05298696
- Testing
- Cilostazol
- Where
- Egypt
- Volunteers
- 71 people
- Sponsor
- Mansoura University
Breast Cancer Female, Neuropathic Pain
Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer
Since its introduction in the 1970s, Paclitaxel has been used as an effective anticancer agent against lung, breast, ovarian, leukopenia and liver cancer.
- Trial name
- NCT03022162
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Tata Memorial Centre
Peripheral Neuropathy
Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel.
- Trial name
- NCT01313117
- Testing
- Alpha lipoic acid
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Neuropathic Pain, Chemotherapy Effect
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Phase IIa clinical trial will be conducted with patients requiring in-label paclitaxel-chemotherapy due to ovarian or breast cancer.
- Trial name
- PrevTel (NCT05322889)
- Testing
- Telmisartan tablets
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Dr. Frank Behrens
Peripheral Neuropathy, Secondary to Drugs or Chemicals, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy.
- Conditions
- Peripheral Neuropathy, Secondary to Drugs or Chemicals, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Paclitaxel Induced Neuropathy
- Trial name
- EX-CIPN (NCT07399561)
- Testing
- Exercise Intervention, Usual Care
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- National Cancer Center, Korea
Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
This early phase/phase II trial tests the safety, side effects, and best dose of monosialotetrahexosylganglioside (GM1) and whether it works in reducing or preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
- Trial name
- NCT05751668
- Testing
- Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration
- Where
- 33 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
Chemotherapy-induced Peripheral Neuropathy
Pentoxifylline Role Against Chemotherapy-induced Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of neurotoxic cancer treatment. Estimated to occur in up to 80% of paclitaxel-treated patients with breast cancer, neuropathy symptoms can…
- Trial name
- NCT06562998
- Testing
- Pentoxifylline
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Beni-Suef University
Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy
This research study is for participants who are receiving paclitaxel infusion as part of their cancer treatment. The purpose of this study is to test the effectiveness of the Food and Drug Administration (FDA) approved…
- Trial name
- NCT07834281
- Testing
- High Concentration Capsaicin Patch (HCCP)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Case Comprehensive Cancer Center
Cognition Disorders, Polyneuropathies
Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer
Neurotoxic phenomena are among the most common and difficult to treat side effects of chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a well-recognized adverse reaction in the peripheral…
- Trial name
- CICARO (NCT02753036)
- Testing
- Chemotherapy
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Charite University, Berlin, Germany
Cryotherapy Effect, Peripheral Neuropathy
The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer
This study will determine the efficacy of cryotherapy to prevent paclitaxel-induced peripheral neuropathy and nail changes in women with breast cancer.
- Conditions
- Cryotherapy Effect, Peripheral Neuropathy, Nail Toxicity
- Trial name
- NCT04558034
- Testing
- cryotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Parkview Health
Peripheral Neuropathy Due to Chemotherapy
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer
- Trial name
- NCT04461977
- Testing
- True acupuncture
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Peripheral Neuropathy Due to Chemotherapy
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure.
- Trial name
- NCT06135493
- Testing
- Losartan
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Future University in Egypt